Pages that link to "Q15756361"
Jump to navigation
Jump to search
The following pages link to HIV Clinical Trials (Q15756361):
Displaying 50 items.
- (Q20828722) (redirect page) (← links)
- Rates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral Centers (Q27491310) (← links)
- Protease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach? (Q28190771) (← links)
- Human immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies? (Q28283307) (← links)
- High-level immunogenicity is achieved vaccine with adjuvanted pandemic H1N1(2009) and improved with booster dosing in a randomized trial of HIV-infected adults. (Q30412595) (← links)
- Feasibility and reliability of interactive voice response assessment of HIV medication adherence: research and clinical implications (Q30419385) (← links)
- Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies (Q30654030) (← links)
- Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data (Q30795793) (← links)
- Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort (Q30843946) (← links)
- The maraviroc expanded access program - safety and efficacy data from an open-label study (Q30911112) (← links)
- Evaluation of multiple failure time analyses of observational data in patients treated for HIV. (Q30993093) (← links)
- Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations (Q31046396) (← links)
- Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study (Q31076943) (← links)
- An example of nonrandom missing data for hepatitis C virus status in a prognostic study among HIV-infected patients (Q33207755) (← links)
- Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy (Q33407077) (← links)
- Functional impairments of microcirculation in HIV-positive patients: a laser Doppler fluxometry-based investigation (Q33407079) (← links)
- The efficacy and safety of probiotic Lactobacillus rhamnosus GG on prolonged, noninfectious diarrhea in HIV Patients on antiretroviral therapy: a randomized, placebo-controlled, crossover study (Q33432290) (← links)
- Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection (Q33436334) (← links)
- A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. (Q33447663) (← links)
- Site nurse-initiated adherence and symptom support telephone calls for HIV-positive individuals starting antiretroviral therapy, ACTG 5031: substudy of ACTG 384. (Q33602445) (← links)
- Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience (Q33649563) (← links)
- Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials (Q33653481) (← links)
- Higher plasma myeloperoxidase levels are not associated with an increased risk for cardiovascular events in HIV-infected adults (Q33691689) (← links)
- Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. (Q33705707) (← links)
- Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202. (Q33767281) (← links)
- Effect of tuberculosis preventive therapy on HIV disease progression and survival in HIV-infected adults (Q33813132) (← links)
- Similar Efficacy of Raltegravir When Used With or Without a Protease Inhibitor in Treatment-Experienced Patients (Q33935930) (← links)
- Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adults (Q33936089) (← links)
- Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial (Q33961434) (← links)
- Genetic predictors of cervical dysplasia in African American HIV-infected women: ACTG DACS 268. (Q33988391) (← links)
- Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study (Q34112020) (← links)
- Monitoring medication adherence by unannounced pill counts conducted by telephone: reliability and criterion-related validity (Q34118239) (← links)
- Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164. (Q34202331) (← links)
- Failure to identify HIV-infected individuals in a clinical trial using a single HIV rapid test for screening (Q34205686) (← links)
- Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s) (Q34216364) (← links)
- Vicriviroc and peripheral neuropathy: results from AIDS Clinical Trials Group 5211. (Q34216388) (← links)
- Memantine for AIDS dementia complex: open-label report of ACTG 301. (Q34312179) (← links)
- Cholecalciferol supplementation in HIV-infected youth with vitamin D insufficiency: effects on vitamin D status and T-cell phenotype: a randomized controlled trial. (Q34340891) (← links)
- Sustained virological response and baseline predictors in HIV-HCV coinfected patients retreated with pegylated interferon and ribavirin after failing a previous interferon-based therapy: systematic review and meta-analysis (Q34362476) (← links)
- Clinical utility of monitoring serum cryptococcal antigen (sCRAG) titers in patients with AIDS-related cryptococcal disease (Q34394657) (← links)
- Efficacy of a nelfinavir- and nevirapine-containing salvage regimen (Q34394663) (← links)
- Measuring adherence to antiretroviral medications in clinical trials (Q34394669) (← links)
- Therapeutic options for the management of oropharyngeal and esophageal candidiasis in HIV/AIDS patients (Q34394677) (← links)
- Efficacy of nelfinavir in patients switched from ritonavir/saquinavir combination antiretroviral therapy (Q34394684) (← links)
- Problems with publishing results of interim analyses of randomized clinical trials (Q34394689) (← links)
- HIV lipodystrophy: a review (Q34394698) (← links)
- Vertical transmission of HIV in Africa: diagnostic testing and new interventions (Q34394705) (← links)
- Antiretroviral treatments to reduce mother-to-child transmission of HIV. (Q34394712) (← links)
- Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations (Q34394720) (← links)
- Tuberculosis and HIV infection: epidemiology, immunology, and treatment (Q34394728) (← links)